|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 282, Issue 22, 16232-16243, June 1, 2007
Biochemical and Functional Characterization of Orai Proteins*
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although the notion of Ca2+ influx through "store-operated" Ca2+ channels was first proposed in 1986 (4, 5), the molecular identity of the proteins involved in this process remained unknown until the advent of large-scale RNAi-based screens. The first components of the pathway to be identified were Drosophila Stim (dStim) and its human homologues STIM1 and STIM2 through large-scale (albeit not genome-wide) RNAi-based screens in Drosophila and HeLa cells, respectively (6, 7). STIM proteins are single-pass transmembrane proteins localized predominantly in the membrane of the endoplasmic reticulum (ER); they contain an N-terminal EF-hand located in the ER lumen and appear to function as sensors of ER Ca2+ levels (69). Upon store depletion, STIM1 relocalizes into puncta that were suggested to represent foci of insertion into the plasma membrane (10) but are more likely points of apposition of the ER and plasma membranes (7, 11, 12). It is thought that within these puncta, STIM1 communicates with and opens CRAC channels located in the plasma membrane (13).
More recently, genome-wide RNAi screens performed in Drosophila cells by our laboratory (14) and others (15, 16) have identified a CRAC channel component, olf186-F. We have renamed this protein Drosophila Orai (dOrai). Its three human homologues, Orai1, Orai2, and Orai3 (also known as CRACM1, CRACM2 and CRACM3 (15, 17), are encoded by the genes TMEM142A, TMEM142B, and TMEM142C (HUGO Gene Nomenclature Committee). Orai1 bears the causal mutation in a severe combined immunodeficiency (SCID) syndrome characterized by a defect in CRAC channel function and T cell cytokine expression (14, 18, 19). Combined overexpression of dOrai and dSTIM in Drosophila cells or Orai1 and STIM1 in Jurkat T cells, RBL cells, or HEK293 cells results in a dramatic increase in ICRAC (16, 20, 21). Amino acid substitutions in either of two conserved glutamate residues, located in predicted transmembrane segments of dOrai and Orai1, changed the properties of ICRAC, suggesting strongly that these proteins are pore subunits of the CRAC channel (16, 17, 22, 23).
Here we compare the properties of the three mammalian Orai proteins. We show that all three are widely expressed at the mRNA level and all can be incorporated into the plasma membrane when ectopically expressed. Orai1 forms homodimers and homomultimers in cells and in detergent solutions, can heteromultimerize with Orai2 and Orai3 as judged by co-immunoprecipitation, and has a predominant role in store-operated Ca2+ entry in HEK293 cells and human T cells and fibroblasts when stores are depleted with thapsigargin. Immunocytochemical analysis shows that ectopically expressed Orai1 and STIM1 colocalize partially in thapsigargin-stimulated T cells. We have generated dominant-interfering forms of dOrai and human Orai1 by substituting glutamine residues in place of either of two highly conserved glutamates located in the first and third predicted transmembrane segments. We show that ectopic expression of the E106Q and E190Q mutants of Orai1 in primary murine T cells severely impairs store-operated Ca2+ influx, proliferation, and cytokine production, consistent with our previous conclusion that Orai1 is a major contributor to T lymphocyte function and the adaptive immune response (14).
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
PlasmidsFull-length cDNAs for Orai1 (BC015369 [GenBank] ), Orai2 (BC069270 [GenBank] ), and Orai3 (BC022786 [GenBank] ) were purchased from OpenBiosystems (Huntsville, AL) and subcloned into pENTR11 ("Gateway" system; Invitrogen) for use in retroviral transductions. For Myc-tagged human Orai proteins, the c-Myc epitope tag (peptide sequence, EQKLISEEDL; nucleotide sequence, GAACAAAAACTTATTTCTGAAGAAGATCTG) was placed in-frame immediately following the cDNA sequences of Orai1, 2, and 3, respectively (i.e. C-terminal Myc tag). The endogenous stop codon was replaced with GAG encoding the first E of the Myc tag; at the end of the Myc sequence a stop codon (TAG) was added to terminate translation. For retroviral expression plasmids encoding human Orai proteins, Orai1, 2, and 3 cDNAs with FLAG epitope tags introduced at the C terminus were cloned between the XhoI and EcoRI sites of pMSCV-CITE-eGFP-PGK-Puro. The endogenous termination codon was substituted with the coding sequence of the FLAG tag (AADYKDDDDK) followed by a TAG termination codon. For mutagenesis of Orai1, the QuikChange site-directed mutagenesis kit (Invitrogen) was used according to the manufacturer's instructions. HA epitope tags were introduced within the second extracellular loop of Orai1 (22), Orai2, and Orai3 by first introducing SalI and MluI restriction enzyme sites between codons 206 and 207 of Orai1, codons 188 and 189 of Orai2, and codons 194 and 195 of Orai3, respectively, followed by ligation of a double-stranded oligonucleotide encoding the HA peptide flanked by a glycine-serineglycine-serine linker on either side: 5'-TC GAC GGC AGC GGC AGC TAC CCA TAC GAT GTT CCA GAT TAC GCT GGC AGC GGC AGC A-3'.
For FLAG-tagged dOrai, the FLAG sequence was placed inframe immediately after the coding sequence of dOrai. The endogenous stop codon was replaced with the first codon of the FLAG epitope tag; at the end of the FLAG sequence a TAG stop codon was added to terminate translation. S2R+ cells were stably transfected with wild-type or mutant dOrai subcloned into the expression plasmid pAc5.1 (Invitrogen), which adds a V5 tag to the C terminus of the coding sequences of dOrai. S2R+ cells were co-transfected with pAc5.1 dOrai and a hygromycin resistance gene under the control of a constitutively active promoter (pCoHygro; Invitrogen) at a ratio of 19:1. Cells were selected for 34 weeks with 300 µg/ml hygromycin, and stable clones were selected by visual inspection.
AntibodiesAnti-FLAG monoclonal antibody was purchased from Sigma (M2 clone), anti-HA monoclonal antibody (12CA5) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-STIM1 monoclonal antibody was purchased from BD Biosciences. Anti-Myc (9E10) monoclonal antibody was purified from hybridoma supernatants in our laboratory.
Genome-wide Drosophila RNAi ScreenThe genome-wide RNAi screen in Drosophila was performed at the Drosophila RNAi Screening Center at Harvard Medical School as previously described (2528). 104 S2R+ cells stably expressing NFAT1-(1460) GFP were added into each well of a 384-well plate containing 0.25 µg of double-stranded RNAs in 10 µl of serum-free medium and incubated for 1 h at 24 °C, followed by addition of 30 µl of complete medium. After incubation for 4 days at 24 °C, the cells were treated with 1 µM thapsigargin for 10 min, fixed, and stained with 4',6-diamidino-2-phenylindole, and the coincident GFP and 4',6-diamidino-2-phenylindole images were acquired by an automated camera from three different locations in each well. A total of 63 384-well plates were analyzed, containing a total of
23,770 wells into which individual double-stranded RNAs had been arrayed. The whole genome-wide screen was duplicated to improve the accuracy and check the reproducibility of the screen.
Secondary RNAi Screen Measuring Thapsigargin-induced Ca2+ EntryThe primary screen identified 16 candidates whose RNAi-mediated depletion interfered with NFAT nuclear import, including calmodulin and the catalytic (CanA-14F) and regulatory (CanB) subunits of calcineurin as expected (25). With the exception of calcineurin and calmodulin, the remaining 13 candidates were re-evaluated in a secondary screen using double-stranded RNAs listed on the Drosophila RNAi Screening Center Web site (2628). PCR fragments (size up to 600 bp) were used as templates for in vitro transcription reactions, followed by DNase I treatment to remove the template DNA. After purification, double-stranded RNA (5 µg) was transfected into S2R+ cells in 12-well plates. After 4 days of incubation, Ca2+ influx in S2R+ cells was measured by flow cytometry. Cells were detached from the dish with trypsin (CellGro, Herndon, VA) and then loaded with the Ca2+ indicator dyes Fluo4-AM and Fura-Red (2 µM each; Invitrogen) for 45 min at room temperature in Schneider's medium containing 10% fetal calf serum. Immediately prior to flow cytometry, cells were resuspended in Ringer solution containing no added Ca2+ and analyzed for basal levels of intracellular free Ca2+ ([Ca2+]i) on a FACSCalibur flow cytometer (BD Biosciences). After 30 s, thapsigargin (3 µM) was added to deplete ER Ca2+ stores. An equal volume of Ringer solution containing 4 mM Ca2+ was added to the samples (final [Ca2+]ex 2 mM), and [Ca2+]i levels were monitored for 300 s. The ratio of Fluo-4 and Fura-Red emission was analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).
Northern BlotsNorthern blotting was performed on the First Choice Human Northern Blot I (Ambion, Foster City, CA) according to the manufacturer's protocol. The probes were PCR-labeled using Strip-EZ PCR probe synthesis and removal kit (Ambion) according to the manufacturer's instructions. The primers used to generate probes for the 3'-untranslated regions of the human Orai were as follows: Orai1, CCCTTCCAGTGCTTTGGCCTTA and GTGTCACACACACATGTACACACTC; Orai2, AGGGACTGTGTTGCTAAGAGCGTT and CGTACTTTGCAGCAGCCCTCAAAT; and Orai3, TTGTGGGACCTTCAGTGCTGACTT and AACAAGTTTGGTGCATAGCGTGGG. For Northern blot analysis of murine tissues, total RNA was extracted using TRIzol reagent (Invitrogen), and 20 µg of RNA was separated by electrophoresis on a 1% agarose/formaldehyde gel and transferred onto Nytran SuPerCharge membrane (Schleicher and Schuell Bioscience). [
-32P]dCTP-labeled probes (random prime labeling mix; Pharmacia) were synthesized for mouse Orai1 or GAPDH and purified using Sephadex G50 spin column (Pharmacia). Primers for generation of the mouse Orai1 probe were CGAGTCACAGCAATCCGGAGCTTC and TGGTTGGCGACGATGACTGATTCA. Primers for generation of the GAPDH probe were CCATCACCATCTTCCAGGAG and CCTGCTTCACCACCTTCTTG. CD4+ T cells were purified from lymph nodes using antibody-coated magnetic beads (Dynabeads; Dynal, Invitrogen). B220+ cells were purified from spleen using MACS beads (Miltenyi Biotech, Auburn, CA).
siRNA-mediated Depletion and Real-time PCR0.5 x 106 HEK293 cells/well were seeded in 12-well plates and transfected the next day with control or experimental siRNAs (Dharmacon, Inc., Lafayette, CO) using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol. Cells were reseeded and the transfection procedure was repeated after 24 h to increase the efficiency of knock down. Cells were harvested for real-time PCR or [Ca2+]i measurement 3 days after transfection. The siRNA sequences correspond to Orai1, UCACUGGUUAGCCAUAAGA; Orai2, CUACCACCACUCGGUACA; Orai3, UUGAAGCUGUGAGCAACAU. Knock down efficiency was quantified by quantitative PCR analysis using the Taqman method. Briefly, RNA was purified with TRIzol LS reagent (Invitrogen) and oligo(dT)-primed for first-strand cDNA synthesis (Superscript II kit; Invitrogen) according to the manufacturer's instructions. Quantitative 5'-nuclease fluorogenic real-time PCR (Taqman) was performed with an ICycler IQ (Bio-Rad). Primers for PCR spanned an intron to exclude contamination with genomic DNA. The amplified cDNA was normalized to GAPDH and expressed as percentage relative to samples treated with control siRNAs ("scrambled" siRNA from Dharmacon). Sequences of primers and probes are tabulated in Table 1.
|
|
-glycerophosphate, 10 mM sodium pyrophosphate, 0.1 mM sodium orthovanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin) and then centrifuged at 100,000 x g for 1 h at 4 °C before preclearing for 2 hat 4 °C with 25 µl of packed protein G-Sepharose. Lysates were immunoprecipitated overnight at 4 °C with anti-FLAG resin (Sigma). In some experiments, cells were pretreated with 2 µg/ml tunicamycin (Sigma) for 18 h before harvesting and lysis. Immunoprecipitates were washed four times in lysis buffer and resolved by 10% SDS-PAGE, and proteins were detected by immunoblotting. S2R+ cells were transiently transfected with Drosophila expression vectors. After 48 h, cells were lysed in Triton lysis buffer, precipitated with anti-FLAG resin, and analyzed by immunoblotting with antibodies to FLAG, Myc, or V5 epitope tags. Glycerol Gradient Analysis2 x 108 Jurkat T cells, stably transfected with FLAG-tagged Orai1, were left untreated or treated with thapsigargin for 10 min in PBS. Cells were lysed in Triton lysis buffer, cleared by centrifugation, and diluted to 0.5% Triton X-100. The lysates were applied to 1040% glycerol cushion and centrifuged at 55,000 rpm for 12 h at 4 °C. A total of 42 fractions were collected from the top, and the fractions between 10 (top) and 40 (bottom) were analyzed by immunoblotting with anti-FLAG antibody. Molecular weights were estimated from the results of parallel experiments with size marker proteins.
Dithiobis(succinimidyl propionate) Cross Linking107 HEK293 cells, stably expressing FLAG-tagged Orai1, were left untreated or treated with thapsigargin for 10 min and then harvested in PBS and cross-linked with 1 mM dithiobis(succinimidyl propionate) for 1 h on ice, followed by quenching with 20 mM Tris-Cl, pH 7.5. Cells were lysed in Triton lysis buffer (see above), precleared, and immunoprecipitated overnight at 4 °C with anti-FLAG resin (Sigma). Immunoprecipitates were washed four times in lysis buffer and resolved by 10% SDS-PAGE, and Orai1 was detected by immunoblotting with anti-FLAG antibodies.
T Cell DifferentiationMurine CD4+ cells were purified by magnetic bead separation (Dynal, Invitrogen) from spleen and lymph nodes of young (35-week-old) C57BL/6J mice following the manufacturer's protocols. The purity of CD4+ T cells in different preparations was >95%. Cells were stimulated with anti-CD3 and anti-CD28 under Th1 conditions and expanded in IL-2-containing medium as previously described (29).
Intracellular Cytokine Staining and Proliferation AssaysFor intracellular cytokine staining, T cells were stimulated with 10 nM phorbol 12-myristate 13-acetate (PMA) and 1 µM ionomycin for 4 h. Brefeldin A (10 µg/ml; Sigma) was included during the final 2 h of stimulation. Cells were fixed with 4% paraformaldehyde in PBS for 8 min at 25 °C, washed twice with PBS, and permeabilized in saponin buffer (PBS, 0.5% saponin, 1% bovine serum albumin, and 0.1% sodium azide). Cells were washed three times in saponin buffer and twice in PBS and were analyzed with a FACSCalibur flow cytometer (BD Biosciences) and FlowJo software. Phycoerythrin anti-IL-2 and allophycocyanin anti-IFN-
antibodies were purchased from eBioscience (San Diego, CA). BrdUrd incorporation assays were performed according to the manufacturer's instructions (BD Biosciences). Briefly, T cells were stimulated with 10 nM PMA and 1 µM ionomycin for 30 min and cultured in medium without IL-2 to assess autocrine proliferation. The next day, cells were pulsed with BrdUrd for 60 min, stained with phycoerythrin-conjugated anti-BrdUrd monoclonal antibody (Pharmingen), and analyzed with a FACSCalibur flow cytometer (BD Biosciences) to measure BrdUrd incorporation.
|
[Ca2+]i Measurements in Drosophila Cells[Ca2+]i measurements in S2R+ cells stably transfected with wild-type or mutant dOrai were performed by flow cytometry, essentially as described for the secondary screen.
Single-cell Ca2+ Imaging[Ca2+]i measurements in mouse primary T cells or SCID fibroblasts were carried out by single-cell video imaging as previously described (14, 18).
| RESULTS |
|---|
|
|
|---|
|
|
We used RNAi-mediated depletion to ask whether Orai2 and Orai3 resembled Orai1 in regulating store-operated Ca2+ entry. HEK293 cells and Jurkat T cells were transfected with siRNAs directed against Orai2 and Orai3 and then cultured for 3 days before analysis of Ca2+ influx. Orai1 was used as a positive control. Depletion of Orai1 decreased thapsigargin-stimulated Ca2+ influx as expected (11, 14, 15, 22, 33), whereas depletion of Orai2 and Orai3 had little or no effect (Fig. 1, C and D; data not shown for Jurkat T cells). The siRNAs were effective in diminishing transcript levels of the corresponding mRNAs in HEK293 cells, as shown by reverse transcription PCR (Fig. 1C). Unexpectedly, however, depletion of Orai3 caused a large increase in mRNA levels of Orai1, possibly due to a compensatory feedback mechanism (Fig. 1C). We therefore independently evaluated Orai function by measuring the ability of Orai proteins to restore store-operated Ca2+ entry when expressed in cells from ICRAC-deficient SCID patients (19) bearing an R91W mutation in Orai1 (14). As shown previously (14), Orai1 efficiently complemented store-operated Ca2+ influx in SCID T cells and fibroblasts; in contrast, Orai2 and Orai3 reconstituted poorly or not at all (Fig. 2 and supplemental Fig. S1A). However, SCID fibroblasts transduced with Orai3 showed a small amount of store-operated Ca2+ entry, which was blocked by La3+ (supplemental Fig. S1A) and eliminated by mutation of the conserved glutamate residue in the first predicted transmembrane domain of Orai3 (E81Q, corresponding to the E106Q mutation in Orai1 described below; Fig. 2B). Moreover, combined overexpression of Orai3 and STIM1 resulted in substantial reconstitution of Ca2+ entry in SCID fibroblasts, whereas combined overexpression of Orai2 and STIM1 had little effect (supplemental Fig. S1B). Combined overexpression of Orai1 and STIM1 did not increase store-operated Ca2+ entry significantly above the level observed with Orai1 alone (supplemental Fig. S1B and data not shown).
One explanation for the weaker reconstitution by Orai2 and Orai3 could have been that these proteins were poorly expressed relative to Orai1 or were not inserted into the plasma membrane. However, immunocytochemistry of tagged proteins expressed in Jurkat T cells and HEK293 cells confirmed that all three Orai proteins were expressed and localized at or near the plasma membrane, showing little or no overlap with the ER marker ERP72 (Fig. 3A and data not shown); localization was not grossly altered after store depletion with thapsigargin (Fig. 3A). To confirm plasma membrane localization, we generated versions of all three Orai proteins bearing HA epitope tags in the predicted TM3-TM4 loop as previously described for Orai1 (22) and expressed them in HEK293 cells. Immunocytochemical analysis demonstrated that the HA tag is extracellular, that is, accessible to antibody staining in intact, unpermeabilized cells (Fig. 3B). Thus, all three Orai proteins can be inserted into the plasma membrane. Taken together, these data show unambiguously that in HEK293 cells and human SCID T cells and fibroblasts in which store depletion has been induced with thapsigargin, Orai1 is the major regulator of store-operated Ca2+ influx, whereas Orai3 can complement partially and Orai2 has a lesser role.
|
45 kDa, significantly larger than the molecular mass (
33 kDa) deduced from its amino acid sequence; however, treatment of the Orai1-expressing cells with tunicamycin, an inhibitor of the first step of glycosylation in the ER, caused the Orai1 band to shift to a position close to the predicted size (Fig. 4A, panels 1 and 2). In contrast, Orai2 and Orai3 migrated at positions close to their predicted molecular masses of 28 and 32.5 kDa, respectively, and their migration properties were not changed by tunicamycin treatment (Fig. 4A, panels 3 and 4). Glycosylation is not required for Orai1 function, however: both the NVS >IVI and N223A mutations abolished the glycosylation of Orai1 without affecting its localization within the cell (22) (Fig. 4B, top and middle panels), but the mutant proteins were at least as effective as wild-type Orai1 at reconstituting store-operated Ca2+ influx in SCID patient cells (Fig. 4B, bottom, and Fig. 4C and data not shown).
|
45-kDa form (Fig. 5A, panel 1), whereas the transiently overexpressed Myc-Orai1 migrated as glycosylated and unglycosylated forms of
45 and
33 kDa, respectively; this was shown by digestion of anti-Myc immunoprecipitates with peptidyl N-glycosidase F, which releases N-glycans from glycosylated asparagine residues (Fig. 5A, panels 1 and 2). The two forms of Orai1 interacted with one another, as shown by immunoblotting anti-FLAG immunoprecipitates with anti-Myc antibody (Fig. 5A, panels 3 and 4). Using HEK293 cells stably expressing FLAG-tagged Orai2 and Orai3, we also observed co-immunoprecipitation of Orai2 and Orai3 with transiently overexpressed Myc-Orai1 (Fig. 5B, panel 3). Thus, Orai1 forms homomultimers and can also form heteromultimers with Orai2 and Orai3.
|
8590 kDa (fractions 1622 in the two upper panels), suggesting that the major Orai1 complex is a dimer of the glycosylated
45-kDa form. Orai1 in these fractions migrated on SDS gels as two major bands, corresponding to the glycosylated monomer (
45 kDa) and an SDS-resistant dimer (
90 kDa) that we observe in occasional experiments (Fig. 5C, top panels). Cross-linking experiments using the cell-permeant reversible cross-linker dithiobis(succinimidyl propionate) demonstrated the existence of
100 and
200-kDa Orai1 complexes in both resting and thapsigargin-treated cells (Fig. 5D), potentially corresponding to dimers and higher-order multimers (possibly tetramers) of Orai1. STIM1 migrated in the glycerol gradients as a monomer of expected molecular mass
90 kDa, indicating that it does not form a stable complex with Orai1 under these detergent conditions (Fig. 5C, bottom panels, fractions 1622). However, immunocytochemistry showed that STIM1 and Orai1 colocalized at least partially in thapsigargin-treated Jurkat cells (supplemental Fig. S3), consistent with recent findings that STIM1 and Orai1 colocalize after store depletion (13, 34) at sites of Ca2+ entry (13). Generation of Dominant-interfering Versions of Drosophila OraiThe fact that Orai1 existed as at least a dimer in cell lysates suggested that inactive mutant versions of the protein might exert a dominant-interfering effect, by sequestering essential components or by forming mixed dimers or higher-order multimers with native wild-type subunits. We evaluated this hypothesis initially in Drosophila cells, first confirming that Drosophila Orai was a multimer in coimmunoprecipitation experiments (Fig. 6A) and then testing the effect of glutamine substitutions in four highly conserved glutamate residues located within or near transmembrane regions (Glu-178, Glu-221, Glu-245, and Glu-262; numbering based on GenBankTM accession number AY071273 [GenBank] ; Fig. 6B and supplemental Fig. S2). We generated S2R+ cells stably expressing V5-tagged dOrai proteins with glutamine substitutions at each of these conserved residues and assessed store-operated Ca2+ entry by flow cytometry (Fig. 6C). Expression of the E178Q and E262Q mutants led to a strong decrease in store-operated Ca2+ entry, expression of the wild-type and E245Q proteins led to at most a 2-fold decrease, and expression of the E221Q mutant had almost no effect compared with a vector control (Fig. 6C and data not shown).
Dominant-interfering Versions of Human Orai1 Block Lymphocyte FunctionWe used the information from the Drosophila experiments to construct dominant-interfering versions of human Orai1. We generated mutant proteins in which glutamates Glu-106 and Glu-190 of human Orai1, corresponding to Glu-178 and Glu-262 of dOrai (Fig. 6B and supplemental Fig. S2), were substituted with glutamine. When expressed in wild-type human fibroblasts and primary mouse CD4+ T cells, the mutants were expressed at levels comparable with wild-type Orai1 and were localized at or near the plasma membrane (supplemental Fig. S4). Paralleling the findings in Drosophila cells (Fig. 6C), overexpression of the E106Q and E190Q mutants of Orai1 in human fibroblasts suppressed store-operated Ca2+ entry (Fig. 6D).
We examined the effect of the mutant proteins on lymphocyte function (Fig. 7). Primary mouse CD4+ T cells were expanded in vitro with anti-CD3 and anti-CD28 under Th1 conditions (29) and transduced with retroviruses encoding FLAG-tagged wild-type Orai1 or the E106Q or E190Q mutants of Orai1, together with GFP, in a bicistronic vector in which an internal ribosomal entry site (IRES) was followed by GFP cDNA. Ca2+ influx was evaluated in GFP-positive cells following thapsigargin stimulation. This analysis confirmed that the E106Q or E190Q mutants of Orai1 exerted a dominant-interfering effect on store-operated Ca2+ influx in mouse T cells (Fig. 7A). Furthermore, T cells expressing either of the mutants showed severely reduced proliferation in response to stimulation with PMA and ionomycin, as judged by BrdUrd incorporation (Fig. 7B). This deficiency was most likely due to decreased IL-2 production secondary to reduced Ca2+ influx. T cells transduced with the mutant Orai1 proteins showed a strong decrease in production of both IFN-
and IL-2 after stimulation with PMA and ionomycin for 4 h (Fig. 7C).
|
| DISCUSSION |
|---|
|
|
|---|
Notably, only dStim and dOrai were identified in three independent genome-wide RNAi screens in Drosophila, our NFAT-based screen as well the two Ca2+-based screens (Refs. 1416 and this report). The splicing factor Noi emerged as a candidate both in our screen and in the screen performed by Vig et al. (15) but was excluded as a regulator of store-operated Ca2+ entry in our secondary screen. The kinesin family member Pav was identified both in our screen and by Zhang et al. (16) and could potentially participate in STIM relocalization. Unfortunately, however, Pav depletion in Drosophila cells caused a severe mitotic arrest phenotype, presumably reflecting the known role of Pav in cytokinesis (30), and thus we were unable to establish a direct role for Pav in store-operated Ca2+ influx. Depletion of the SNARE protein Syntaxin 5, which is involved in vesicle fusion, was shown by Zhang et al. (16) to inhibit store-operated Ca2+ influx by 2- to 3-fold, but this protein was not identified in our screen or in that performed by Vig et al. (15). The robust identification of dOrai and dStim in all three screens is consistent with the finding that combined overexpression of dOrai and dStim in Drosophila cells greatly increases store-operated Ca2+ entry (16). The implication is that other components are not limiting, possibly because they are stable proteins that are difficult to deplete by RNAi.
It has been shown that STIM1 and Orai1 colocalize after store depletion (13, 34) and that the sites of colocalization coincide with sites of Ca2+ entry (13). In addition, there have been recent reports of physical interactions between ectopically expressed STIM and Orai: a resting interaction of human STIM1 with human Orai1 was observed in cells whose Ca2+ stores are replete (17), and store depletion was reported to induce a further association of Drosophila Stim with Drosophila Orai (23). In our hands, co-immunoprecipitation experiments have failed to demonstrate a tight association between human Orai1 and STIM1 in any of several detergent and salt conditions tested (Fig. 5 and data not shown). The interaction, if direct, may be of low affinity (rapidly dissociating) or may involve intermediary proteins.
We previously described SCID patients whose T lymphocytes exhibit a multiple cytokine deficiency, secondary to a severe defect in CRAC channel function (18, 19). We have shown that the causal molecular defect in these patients is a point mutation in the CRAC channel pore subunit Orai1 (14, 22). Reconstitution of SCID cells with wild-type Orai1 restores store-operated Ca2+ entry and CRAC channel function (Ref. 14 and this report); however, because the retroviral transduction efficiency of the SCID T cells is very low (12%), we were unable to monitor cytokine expression directly in the reconstituted cells. To define the relation of Orai1 activity to lymphocyte function, we instead overexpressed dominant-interfering versions of human Orai1 (E106Q and E190Q) in primary murine T lymphocytes and showed that these proteins interfered simultaneously with store-operated Ca2+ entry, T cell proliferation, and cytokine production (Fig. 7). Together these data emphasize that Orai1 is a major regulator of store-operated Ca2+ influx in human and murine T cells. Given that Orai1 is widely expressed, the most likely explanation for the immune-specific phenotype of the SCID patients is that T cells are much more dependent on store-operated Ca2+ entry through CRAC channels than are other cell types such as neurons, heart and muscle cells, which utilize voltage-gated, ligand-gated, and diverse other Ca2+ channels to mediate Ca2+ influx.
What are the roles of Orai2 and Orai3 in store-operated Ca2+ entry? We have used several parallel approaches to ascertain the contributions of these two Orai proteins relative to Orai1. The predominant role of Orai1 in store-operated Ca2+ entry in T cells and fibroblasts has been demonstrated through siRNA-mediated knock down in HEK293 cells (Fig. 1), by expressing all three Orai proteins in SCID patient cells (Fig. 2 and supplemental Fig. S1), and by showing that overexpression of two dominant-interfering Orai1 mutants, E106Q and E190Q, in primary T cells blocks store-operated Ca2+ entry as well as proliferation and cytokine production (Figs. 6 and 7). However, our results suggest strongly that Orai3 is also functional in store-operated Ca2+ entry. First, the small increase in store-operated Ca2+ entry observed in SCID cells reconstituted with Orai3 is not observed when the E81Q mutant of Orai3 is used instead (Fig. 2). Second, combined expression of STIM1 and Orai3 in SCID T cells leads to a distinct increase in store-operated Ca2+ influx, albeit somewhat smaller in magnitude than that observed in cells co-expressing STIM1 and Orai1 (supplemental Fig. S1). These data are consistent with a previous report demonstrating that Orai2 and Orai3 can partly replace Orai1 in mediating store-operated Ca2+ entry in HEK293 cells (11). Overexpression of Orai2 with STIM1 substantially increased store-operated Ca2+ influx in transfected HEK293 cells (11); likewise, Orai3 was able to restore store-operated Ca2+ entry in HEK293 cells where Orai1 levels were depleted by RNAi (11). Given that (i) Orai1 is a pore subunit of the CRAC channel (17, 22), (ii) all three Orai proteins can be located at the plasma membrane (Fig. 3B), (iii) Orai3 can marginally reconstitute Ca2+ influx in SCID T cells, especially if overexpressed with STIM1 (Fig. 2, supplemental Fig. S1), and (iv) overexpressed Orai1 can coimmunoprecipitate with Orai2 and Orai3 (Fig. 5B), it is likely that Orai2 and Orai3 can multimerize with Orai1 to form cation channels that conduct Ca2+ to some degree. Targeted disruption of the Orai2 and Orai3 genes will be required to define the contributions of Orai2 and Orai3 to store-operated Ca2+ entry in cells and tissues in which they play a role.
| FOOTNOTES |
|---|
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1S4. ![]()
1 Both authors contributed equally to this work. ![]()
2 Supported by a Ford Foundation predoctoral fellowship. A fellow of the Ryan Foundation. ![]()
3 Recipient of a fellowship from Uehara Memorial Foundation. ![]()
4 To whom correspondence should be addressed: Dept. of Pathology, Harvard Medical School, The CBR Institute for Biomedical Research, Rm. 152, Warren Alpert Bldg., 200 Longwood Ave., Boston MA 02115. Tel.: 617-278-3260; Fax: 617-278-3280; E-mail: arao{at}cbr.med.harvard.edu.
5 The abbreviations used are: CRAC, Ca2+ release-activated Ca2+; PMA, phorbol 12-myristate 13-acetate; RNAi, RNA interference; ER, endoplasmic reticulum; SCID, severe combined immunodeficiency; HEK, human embryonic kidney; HA, hemagglutinin; GFP, green fluorescent protein; PBS, phosphate-buffered saline; IL-2, interleukin 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; BrdUrd, bromodeoxyuridine; IFN, interfering; SNARE, soluble NSF attachment protein receptor; siRNA, small interfering RNA; IRES, Internal Ribosomal Entry site. ![]()
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T.-Y. Chiu, H.-C. Teng, P.-C. Huang, F.-J. Kao, and D.-M. Yang Dominant Role of Orai1 with STIM1 on the Cytosolic Entry and Cytotoxicity of Lead Ions Toxicol. Sci., August 1, 2009; 110(2): 353 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Scrimgeour, T. Litjens, L. Ma, G. J. Barritt, and G. Y. Rychkov Properties of Orai1 mediated store-operated current depend on the expression levels of STIM1 and Orai1 proteins J. Physiol., June 15, 2009; 587(12): 2903 - 2918. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Derler, M. Fahrner, O. Carugo, M. Muik, J. Bergsmann, R. Schindl, I. Frischauf, S. Eshaghi, and C. Romanin Increased Hydrophobicity at the N Terminus/Membrane Interface Impairs Gating of the Severe Combined Immunodeficiency-related ORAI1 Mutant J. Biol. Chem., June 5, 2009; 284(23): 15903 - 15915. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Maruyama, T. Ogura, K. Mio, K. Kato, T. Kaneko, S. Kiyonaka, Y. Mori, and C. Sato Tetrameric Orai1 Is a Teardrop-shaped Molecule with a Long, Tapered Cytoplasmic Domain J. Biol. Chem., May 15, 2009; 284(20): 13676 - 13685. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. L. Martin, D. Willoughby, A. Ciruela, L.-J. Ayling, M. Pagano, S. Wachten, A. Tengholm, and D. M. F. Cooper Capacitative Ca2+ Entry via Orai1 and Stromal Interacting Molecule 1 (STIM1) Regulates Adenylyl Cyclase Type 8 Mol. Pharmacol., April 1, 2009; 75(4): 830 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Thompson, O. Mignen, and T. J. Shuttleworth The Orai1 Severe Combined Immune Deficiency Mutation and Calcium Release-activated Ca2+ Channel Function in the Heterozygous Condition J. Biol. Chem., March 13, 2009; 284(11): 6620 - 6626. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Darbellay, S. Arnaudeau, S. Konig, H. Jousset, C. Bader, N. Demaurex, and L. Bernheim STIM1- and Orai1-dependent Store-operated Calcium Entry Regulates Human Myoblast Differentiation J. Biol. Chem., February 20, 2009; 284(8): 5370 - 5380. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Matzner, I. M. Zemtsova, N. T. Xuan, M. Duszenko, E. Shumilina, and F. Lang Ion Channels Modulating Mouse Dendritic Cell Functions J. Immunol., November 15, 2008; 181(10): 6803 - 6809. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Navarro-Borelly, A. Somasundaram, M. Yamashita, D. Ren, R. J. Miller, and M. Prakriya STIM1-Orai1 interactions and Orai1 conformational changes revealed by live-cell FRET microscopy J. Physiol., November 15, 2008; 586(22): 5383 - 5401. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Jardin, J. J. Lopez, G. M. Salido, and J. A. Rosado Orai1 Mediates the Interaction between STIM1 and hTRPC1 and Regulates the Mode of Activation of hTRPC1-forming Ca2+ Channels J. Biol. Chem., September 12, 2008; 283(37): 25296 - 25304. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ji, P. Xu, Z. Li, J. Lu, L. Liu, Y. Zhan, Y. Chen, B. Hille, T. Xu, and L. Chen Functional stoichiometry of the unitary calcium-release-activated calcium channel PNAS, September 9, 2008; 105(36): 13668 - 13673. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gwack, S. Srikanth, M. Oh-hora, P. G. Hogan, E. D. Lamperti, M. Yamashita, C. Gelinas, D. S. Neems, Y. Sasaki, S. Feske, et al. Hair Loss and Defective T- and B-Cell Function in Mice Lacking ORAI1 Mol. Cell. Biol., September 1, 2008; 28(17): 5209 - 5222. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Berra-Romani, A. Mazzocco-Spezzia, M. V. Pulina, and V. A. Golovina Ca2+ handling is altered when arterial myocytes progress from a contractile to a proliferative phenotype in culture Am J Physiol Cell Physiol, September 1, 2008; 295(3): C779 - C790. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Barr, K. M. Bernot, S. Srikanth, Y. Gwack, L. Balagopalan, C. K. Regan, D. J. Helman, C. L. Sommers, M. Oh-hora, A. Rao, et al. Dynamic Movement of the Calcium Sensor STIM1 and the Calcium Channel Orai1 in Activated T-Cells: Puncta and Distal Caps Mol. Biol. Cell, July 1, 2008; 19(7): 2802 - 2817. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Zhang, J. A. Kozak, W. Jiang, A. V. Yeromin, J. Chen, Y. Yu, A. Penna, W. Shen, V. Chi, and M. D. Cahalan Store-dependent and -independent Modes Regulating Ca2+ Release-activated Ca2+ Channel Activity of Human Orai1 and Orai3 J. Biol. Chem., June 20, 2008; 283(25): 17662 - 17671. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Spassova, T. Hewavitharana, R. A. Fandino, A. Kaya, J. Tanaka, and D. L. Gill Voltage Gating at the Selectivity Filter of the Ca2+ Release-activated Ca2+ Channel Induced by Mutation of the Orai1 Protein J. Biol. Chem., May 30, 2008; 283(22): 14938 - 14945. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muik, I. Frischauf, I. Derler, M. Fahrner, J. Bergsmann, P. Eder, R. Schindl, C. Hesch, B. Polzinger, R. Fritsch, et al. Dynamic Coupling of the Putative Coiled-coil Domain of ORAI1 with STIM1 Mediates ORAI1 Channel Activation J. Biol. Chem., March 21, 2008; 283(12): 8014 - 8022. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Parvez, A. Beck, C. Peinelt, J. Soboloff, A. Lis, M. Monteilh-Zoller, Donald. L. Gill, A. Fleig, and R. Penner STIM2 protein mediates distinct store-dependent and store-independent modes of CRAC channel activation FASEB J, March 1, 2008; 22(3): 752 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Lioudyno, J. A. Kozak, A. Penna, O. Safrina, S. L. Zhang, D. Sen, J. Roos, K. A. Stauderman, and M. D. Cahalan Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation PNAS, February 12, 2008; 105(6): 2011 - 2016. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Mignen, J. L. Thompson, and T. J. Shuttleworth Orai1 subunit stoichiometry of the mammalian CRAC channel pore J. Physiol., January 15, 2008; 586(2): 419 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Mignen, J. L. Thompson, and T. J. Shuttleworth Both Orai1 and Orai3 are essential components of the arachidonate-regulated Ca2+-selective (ARC) channels J. Physiol., January 1, 2008; 586(1): 185 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Smyth, W. I. DeHaven, G. S. Bird, and J. W. Putney Jr Role of the microtubule cytoskeleton in the function of the store-operated Ca2+ channel activator STIM1 J. Cell Sci., November 1, 2007; 120(21): 3762 - 3771. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, K. T. Cheng, B. C. Bandyopadhyay, B. Pani, A. Dietrich, B. C. Paria, W. D. Swaim, D. Beech, E. Yildrim, B. B. Singh, et al. Attenuation of store-operated Ca2+ current impairs salivary gland fluid secretion in TRPC1( / ) mice PNAS, October 30, 2007; 104(44): 17542 - 17547. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Varnai, B. Toth, D. J. Toth, L. Hunyady, and T. Balla Visualization and Manipulation of Plasma Membrane-Endoplasmic Reticulum Contact Sites Indicates the Presence of Additional Molecular Components within the STIM1-Orai1 Complex J. Biol. Chem., October 5, 2007; 282(40): 29678 - 29690. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, J. Lu, P. Xu, X. Xie, L. Chen, and T. Xu Mapping the Interacting Domains of STIM1 and Orai1 in Ca2+ Release-activated Ca2+ Channel Activation J. Biol. Chem., October 5, 2007; 282(40): 29448 - 29456. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. I. DeHaven, J. T. Smyth, R. R. Boyles, and J. W. Putney Jr. Calcium Inhibition and Calcium Potentiation of Orai1, Orai2, and Orai3 Calcium Release-activated Calcium Channels J. Biol. Chem., June 15, 2007; 282(24): 17548 - 17556. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |